AAP
ITCI

Arax Advisory Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Arax Advisory Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-284
Closed -$37.5K – 3221
2025
Q1 		$37.5K Buy
284
+143
+101% +$17.8K ﹤0.01% 1060
2024
Q4 		$11.8K Buy
141
+8
+6% +$657 ﹤0.01% 1431
2024
Q3 		$9.73K Buy
133
+36
+37% +$2.71K ﹤0.01% 1426
2024
Q2 		$6.64K Buy
97
+78
+411% +$5.41K ﹤0.01% 1461
2024
Q1 		$1.31K Hold
19
– – ﹤0.01% 1109
2023
Q4 		$1.36K Hold
19
– – ﹤0.01% 1074
2023
Q3 		$990 Hold
19
– – ﹤0.01% 1134
2023
Q2 		$1.2K Hold
19
– – ﹤0.01% 1083
2023
Q1 		$1.03K Buy
19
+3
+19% +$145 ﹤0.01% 1096
2022
Q4 		$847 Hold
16
– – ﹤0.01% 1110
2022
Q3 		$1K Buy
16
+3
+23% +$157 ﹤0.01% 1187
2022
Q2 		$1K Hold
13
– – ﹤0.01% 1140
2022
Q1 		$1K Buy
+13
New +$675 ﹤0.01% 1128

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Arax Advisory Partners's ITCI Position: Q2 2025 in Review

Arax Advisory Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 284 shares — an estimated $37.5K sold.

Arax Advisory Partners first reported a position in ITCI in Q1 2022 and held it in 13 quarters. The position peaked at $37.5K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Arax Advisory Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 284 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $37.5K.
  • Arax Advisory Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 13 quarters.
  • Arax Advisory Partners's Intra-Cellular Therapies Inc. position peaked at $37.5K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Arax Advisory Partners's 13F filing for Q2 2025, filed 12 Aug 2025.